Investment analysts at HC Wainwright initiated coverage on shares ofAriad Pharmaceuticals (NASDAQ:ARIA) in a note issued to investors on Tuesday, StockRatingsNetwork reports. The firm set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 84.21% from the company’s current price Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened today at $7.88 and is currently trading at $7.69. The stock showed a negative weekly performance of -3.92%.
Endocyte, Inc. (NASDAQ:ECYT) was soaked in a lot of positive news last week. First, the company announced positive mid-stage trial results for its lung cancer drug Vynfinit, raising hopes on the company’s pipeline. Also, the European Union regulators recommended adoption of Vynfinit for the treatment of ovarian cancer. Endocyte, Inc. (NASDAQ:ECYT) stock opened at $28.45, in current trading session and currently is at $27.74, by gaining 1.91%.The 52 week range of $8.18-$33.70. Company’s market capitalization is $1.00 billion.
Cytokinetics (NASDAQ:CYTK) major shareholder Eastern Capital Ltd bought 500,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $4,000,000.00. Following the purchase, the insider now directly owns 2,883,845 shares of the company’s stock, valued at approximately $23,070,760. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC. Cytokinetics, Inc. (NASDAQ:CYTK) stock is currently trading at $8.68 .The EPS of the stock is -1.32. Company’s market capitalization is $313.52 million.
Cowen and Company started coverage on shares of Idera Pharmaceuticals (NASDAQ:IDRA) in a research report released on Monday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock opened the session at $4.81, and now is at $4.67. The 52 week range of the IDRA stock remained $0.43-$6.87 and the day range was $4.67-$5.02.